News - Merck & Co, Cardio-vascular


Current filters:

Merck & CoCardio-vascular

Popular Filters

1 to 25 of 40 results

FDA approves Merck & Co’s new blood thinner Zontivity

FDA approves Merck & Co’s new blood thinner Zontivity


The US Food and Drug Administration yesterday approved US pharma giant Merck & Co’s Zontivity (vorapaxar)…

Cardio-vascularMerck & CoPharmaceuticalRegulationUSAZontivity

High potency statins linked to better outcome following a heart attack


A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment…

Cardio-vascularezetimibeMerck & CoPharmaceuticalResearchZetia

FDA advisory panel votes to approve Merck & Co’s vorapaxar

FDA advisory panel votes to approve Merck & Co’s vorapaxar


There was a positive outcome for US pharma giant Merck & Co yesterday, when a US Food and Drug Administration…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationUSAvorapaxarZontivity

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review


US drug giant Merck & Co says it has started a rolling submission to the US Food and Drug Administration…

Cardio-vascularMerck & CoMK-3475North AmericaOncologyPharmaceuticalRegulationUSAvorapaxarZontivity

New ACC and AHA guidelines could increase sales of statins

New ACC and AHA guidelines could increase sales of statins


New clinical guidelines have been published for the treatment of cholesterol in people at high risk of…

AbbVieAstraZenecaCardio-vascularCrestorHealthcareLipitorMerck & CoNorth AmericaPfizerPharmaceuticalTricorUSAZetia

Akrikhin expands deal with Merck & Co


Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

Merck & Co's NDA for vorapaxar accepted for standard review by US FDA


US pharma giant Merck & Co (NYSE: MRK) has said the New Drug Application (NDA) for its once-troubled…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationvorapaxar

Cardiome signs deal with AOP Orphan to market CAF drug Brinavess


Canada-based Cardiome Pharma (TSX: COM) has signed an agreement with Austrian firm AOP Orphan Pharmaceuticals…

AOP OrphanBrinavessCardio-vascularCardiome PharmaMerck & CoPharmaceutical

Cardiome gains European MA rights for Brinavess from Merck & Co


Canada-based Cardiome Pharma (TSX: COM) has announced adoption of the decision by the European Commission…

BrinavessCardio-vascularCardiome PharmaEuropeLicensingMerck & CoPharmaceuticalRegulation

US FDA approves Merck & Co's combo cholesterol drug Liptruzet


The Food and Drug Administration has approved pharma giant Merck & Co's (NYSE: MRK) Liptruzet (ezetimibe…

atorvastatinCardio-vascularezetimibeLiptruzetMerck & CoNorth AmericaPharmaceuticalRegulation

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon


US pharma giant Merck & Co (NYSE: MRK) has entered into a non-exclusive agreement with drug major Bristol-Myers…

Anti-viralsBristol-Myers SquibbCardio-vasculardaclatasvirLicensingMerck & CoMK-5172PharmaceuticalResearchXenon Pharmaceuticals

Merck & Co opens new $120 million manufacturing plant in China


US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Merck & Co gets all clear to continue Vytorin study; FDA warns on Pfizer's Zithromax


US pharma giant Merck & Co said yesterday that the Data Safety Monitoring Board (DSMB) of the IMPROVE-IT…

Antibiotics and Infectious diseasesCardio-vascularMerck & CoNorth AmericaPfizerPharmaceuticalRegulationResearchVytorinZithromax

Niacin causes serious unexpected side-effects, but no worthwhile benefits, for at risk patients


Adding extended-release (ER) niacin to statins does not reduce the chances of high risk patients having…

Cardio-vascularMerck & ConiacinPharmaceuticalResearchTredaptive

EMA Pharmacovigilance committee calls for Tredaptive suspension; contraceptives update


At meetings held last week, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee…

Cardio-vascularEuropeMerck & CoNeurologicalPharmaceuticalRegulationReproductivetetrazepamTredaptive

EMA starts review of Merck & Co's cholesterol drug Tredaptive


The European Medicines Agency said on December 21 that it has started a review of the safety and efficacy…

anacetrapibCardio-vascularEli LillyEuropeevacetrapibMerck & CoPharmaceuticalRegulationTredaptive

Merck & Co to drop Tredaptive development in USA


US drug giant Merck & Co (NYSE: MRK) said yesterday that, following disappointing clinical trial results…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationResearchTredaptive

Germany invalidates Seroquel patent; Merck drops combo diabetes drug development


Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany…

AstraZenecaatorvastatinCardio-vascularDiabetesJanuviaMerck & CoMK-0431ENeurologicalPatentsPharmaceuticalResearchSeroquel XR

Theravance and Merck & Co enter cardiovascular disease accord


Drug developer Theravance (Nasdaq: THRX) has signed a collaboration agreement with pharma giant Merck…

Cardio-vascularLicensingMerck & CoPharmaceuticalTheravance

Merck & Co returns vernakalant rights to Cardiome


Canada-based Cardiome Pharma (Nasdaq: CRME) saw its shares go into free-fall, dropping 54.4% to close…

BrinavessCardio-vascularCardiome PharmaLicensingMerck & CoPharmaceuticalvernakalant

1 to 25 of 40 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top